Effect of brimonidine tartrate 0.15% on night-vision difficulty and contrast testing after refractive surgery

Jayson D. Edwards, Jenna M. Burka, Kraig S. Bower, Richard Stutzman, Denise A. Sediq, Jeff C. Rabin

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose: To evaluate the efficacy of brimonidine tartrate ophthalmic solution 0.15% in patients with night-vision difficulties after laser refractive surgery. Setting: Center for Refractive Surgery, Walter Reed Army Medical Center, Washington, District of Columbia, USA. Methods: Six patients with significant night-vision complaints after refractive surgery were enrolled in this study after other treatable causes of night-vision difficulty such as residual refractive error and dry eye were excluded. Low-contrast visual acuity (LCVA) over a range of contrasts (1.25% to 25%) and small letter contrast sensitivity were tested at photopic (100 cd/m2) and mesopic (1 cd/m2) luminance levels, with and without a standard glare source. Testing was performed before brimonidine tartrate ophthalmic solution 0.15% was administered. Measurements were repeated 1 hour and 1 month after the use of brimonidine tartrate. Results: One hour after using brimonidine tartrate 0.15% solution, patients had significant improvement in LCVA, LCVA with glare, and contrast sensitivity. After 1 month of treatment, all 6 patients reported subjective improvement in night vision and there was a significant difference in performance in mesopic LCVA and mesopic LCVA with glare. The mean pupil size before administration of brimonidine tartrate ophthalmic solution 0.15% was 6.44 mm ± 1.11 (SD). Pupil size 1 hour after instillation had decreased to 4.53 ± 1.27 mm and at 1 month had increased to 6.50 ± 0.94 mm. Conclusion: Brimonidine tartrate ophthalmic solution 0.15% improved contrast sensitivity and acuity and decreased night-vision difficulty for up to 1 month in patients with significant complaints after refractive surgery.

Original languageEnglish (US)
Pages (from-to)1538-1541
Number of pages4
JournalJournal of Cataract and Refractive Surgery
Volume34
Issue number9
DOIs
StatePublished - Sep 1 2008
Externally publishedYes

Fingerprint

Night Vision
Refractive Surgical Procedures
Ophthalmic Solutions
Visual Acuity
Glare
Contrast Sensitivity
Pupil
Refractive Errors
Laser Therapy
Brimonidine Tartrate

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Effect of brimonidine tartrate 0.15% on night-vision difficulty and contrast testing after refractive surgery. / Edwards, Jayson D.; Burka, Jenna M.; Bower, Kraig S.; Stutzman, Richard; Sediq, Denise A.; Rabin, Jeff C.

In: Journal of Cataract and Refractive Surgery, Vol. 34, No. 9, 01.09.2008, p. 1538-1541.

Research output: Contribution to journalArticle

Edwards, Jayson D. ; Burka, Jenna M. ; Bower, Kraig S. ; Stutzman, Richard ; Sediq, Denise A. ; Rabin, Jeff C. / Effect of brimonidine tartrate 0.15% on night-vision difficulty and contrast testing after refractive surgery. In: Journal of Cataract and Refractive Surgery. 2008 ; Vol. 34, No. 9. pp. 1538-1541.
@article{b1aa26f2bf274cde9a9cd37c837c3a07,
title = "Effect of brimonidine tartrate 0.15{\%} on night-vision difficulty and contrast testing after refractive surgery",
abstract = "Purpose: To evaluate the efficacy of brimonidine tartrate ophthalmic solution 0.15{\%} in patients with night-vision difficulties after laser refractive surgery. Setting: Center for Refractive Surgery, Walter Reed Army Medical Center, Washington, District of Columbia, USA. Methods: Six patients with significant night-vision complaints after refractive surgery were enrolled in this study after other treatable causes of night-vision difficulty such as residual refractive error and dry eye were excluded. Low-contrast visual acuity (LCVA) over a range of contrasts (1.25{\%} to 25{\%}) and small letter contrast sensitivity were tested at photopic (100 cd/m2) and mesopic (1 cd/m2) luminance levels, with and without a standard glare source. Testing was performed before brimonidine tartrate ophthalmic solution 0.15{\%} was administered. Measurements were repeated 1 hour and 1 month after the use of brimonidine tartrate. Results: One hour after using brimonidine tartrate 0.15{\%} solution, patients had significant improvement in LCVA, LCVA with glare, and contrast sensitivity. After 1 month of treatment, all 6 patients reported subjective improvement in night vision and there was a significant difference in performance in mesopic LCVA and mesopic LCVA with glare. The mean pupil size before administration of brimonidine tartrate ophthalmic solution 0.15{\%} was 6.44 mm ± 1.11 (SD). Pupil size 1 hour after instillation had decreased to 4.53 ± 1.27 mm and at 1 month had increased to 6.50 ± 0.94 mm. Conclusion: Brimonidine tartrate ophthalmic solution 0.15{\%} improved contrast sensitivity and acuity and decreased night-vision difficulty for up to 1 month in patients with significant complaints after refractive surgery.",
author = "Edwards, {Jayson D.} and Burka, {Jenna M.} and Bower, {Kraig S.} and Richard Stutzman and Sediq, {Denise A.} and Rabin, {Jeff C.}",
year = "2008",
month = "9",
day = "1",
doi = "10.1016/j.jcrs.2008.05.029",
language = "English (US)",
volume = "34",
pages = "1538--1541",
journal = "Journal of Cataract and Refractive Surgery",
issn = "0886-3350",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Effect of brimonidine tartrate 0.15% on night-vision difficulty and contrast testing after refractive surgery

AU - Edwards, Jayson D.

AU - Burka, Jenna M.

AU - Bower, Kraig S.

AU - Stutzman, Richard

AU - Sediq, Denise A.

AU - Rabin, Jeff C.

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Purpose: To evaluate the efficacy of brimonidine tartrate ophthalmic solution 0.15% in patients with night-vision difficulties after laser refractive surgery. Setting: Center for Refractive Surgery, Walter Reed Army Medical Center, Washington, District of Columbia, USA. Methods: Six patients with significant night-vision complaints after refractive surgery were enrolled in this study after other treatable causes of night-vision difficulty such as residual refractive error and dry eye were excluded. Low-contrast visual acuity (LCVA) over a range of contrasts (1.25% to 25%) and small letter contrast sensitivity were tested at photopic (100 cd/m2) and mesopic (1 cd/m2) luminance levels, with and without a standard glare source. Testing was performed before brimonidine tartrate ophthalmic solution 0.15% was administered. Measurements were repeated 1 hour and 1 month after the use of brimonidine tartrate. Results: One hour after using brimonidine tartrate 0.15% solution, patients had significant improvement in LCVA, LCVA with glare, and contrast sensitivity. After 1 month of treatment, all 6 patients reported subjective improvement in night vision and there was a significant difference in performance in mesopic LCVA and mesopic LCVA with glare. The mean pupil size before administration of brimonidine tartrate ophthalmic solution 0.15% was 6.44 mm ± 1.11 (SD). Pupil size 1 hour after instillation had decreased to 4.53 ± 1.27 mm and at 1 month had increased to 6.50 ± 0.94 mm. Conclusion: Brimonidine tartrate ophthalmic solution 0.15% improved contrast sensitivity and acuity and decreased night-vision difficulty for up to 1 month in patients with significant complaints after refractive surgery.

AB - Purpose: To evaluate the efficacy of brimonidine tartrate ophthalmic solution 0.15% in patients with night-vision difficulties after laser refractive surgery. Setting: Center for Refractive Surgery, Walter Reed Army Medical Center, Washington, District of Columbia, USA. Methods: Six patients with significant night-vision complaints after refractive surgery were enrolled in this study after other treatable causes of night-vision difficulty such as residual refractive error and dry eye were excluded. Low-contrast visual acuity (LCVA) over a range of contrasts (1.25% to 25%) and small letter contrast sensitivity were tested at photopic (100 cd/m2) and mesopic (1 cd/m2) luminance levels, with and without a standard glare source. Testing was performed before brimonidine tartrate ophthalmic solution 0.15% was administered. Measurements were repeated 1 hour and 1 month after the use of brimonidine tartrate. Results: One hour after using brimonidine tartrate 0.15% solution, patients had significant improvement in LCVA, LCVA with glare, and contrast sensitivity. After 1 month of treatment, all 6 patients reported subjective improvement in night vision and there was a significant difference in performance in mesopic LCVA and mesopic LCVA with glare. The mean pupil size before administration of brimonidine tartrate ophthalmic solution 0.15% was 6.44 mm ± 1.11 (SD). Pupil size 1 hour after instillation had decreased to 4.53 ± 1.27 mm and at 1 month had increased to 6.50 ± 0.94 mm. Conclusion: Brimonidine tartrate ophthalmic solution 0.15% improved contrast sensitivity and acuity and decreased night-vision difficulty for up to 1 month in patients with significant complaints after refractive surgery.

UR - http://www.scopus.com/inward/record.url?scp=49649094321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49649094321&partnerID=8YFLogxK

U2 - 10.1016/j.jcrs.2008.05.029

DO - 10.1016/j.jcrs.2008.05.029

M3 - Article

VL - 34

SP - 1538

EP - 1541

JO - Journal of Cataract and Refractive Surgery

JF - Journal of Cataract and Refractive Surgery

SN - 0886-3350

IS - 9

ER -